Home About us Contact
|
Home About us Contact | ||
|
|
||
Corneal Neovascularization (corneal + neovascularization)
Selected AbstractsVascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healingACTA OPHTHALMOLOGICA, Issue 5 2004Lisha Gan Abstract. Purpose:,To study the change in expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the rabbit cornea and limbus following a penetrating, central corneal alkali burn. The influence of different cells on VEGF and VEGFR-2 expression was studied by excluding granulocytes from the wound area. Methods:,Fourteen New Zealand white rabbits were subjected to a penetrating, 5-mm diameter, central corneal alkali burn in one eye under general anaesthesia. Seven of the rabbits were given injections of fucoidin for 36 hours. The rabbits were killed after 36 hours and the corneas were excised with a sclera rim and prepared for immunohistochemistry. Results:,Both VEGF and VEGFR-2 are strongly expressed in the frontline of repopulating epithelial, stromal and endothelial cells during wound healing, irrespective of granulocyte presence. Vascular endothelial cells express VEGF strongly after injury, but only in the presence of granulocytes. Conclusion:,Corneal neovascularization requires the presence of granulocytes to stimulate vascular endothelial cells. During wound healing in this area, VEGF is a factor that stimulates proliferation and migration and that is not influenced by granulocytes. [source] Delayed neovascularization in inflammation-induced corneal neovascularization in interleukin-10-deficient miceACTA OPHTHALMOLOGICA, Issue 2 2010Branka Samolov Abstract. Purpose:, To investigate the potential modulatory role of interleukin-10 (IL-10) in the suture model for corneal neovascularization. Methods:, Neovascularized areas were measured on corneal flat-mounts in IL-10,/, and wild-type C57BL6 mice. The inflammatory cellular response was characterized with immunohistochemistry. Gene expression was measured by real-time polymerase chain reaction. Results:, IL-10,/, mice showed a delayed neovascular response compared to wild-type animals at day 6 after suture, when approximately half of the cornea was neovascularized. No apparent differences in inflammatory responses or in messenger RNA (mRNA) expression for proangiogenic factors were detected in IL-10,/, versus wild-type mice. Conclusion:, IL-10 appears to have a proangiogenic effect in the suture model for corneal neovascularization that cannot be explained by either IL-10's anti-inflammatory effect or apparent cross-talk with the angiogenic factors vascular endothelial growth factor (VEGF)-A, metalloproteinase (MMP)-2 and MMP-9, angiopoietin (Ang)-1 and Ang-2. [source] Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularizationACTA OPHTHALMOLOGICA, Issue 6 2009In-Cheon You Abstract. Purpose:, To investigate the efficacy of subconjunctival injection of bevacizumab in the treatment of patients with corneal neovascularization. Methods:, Twenty-nine eyes of 29 patients with corneal neovascularization were treated with subconjunctival injection [1.25 mg/0.05 ml (seven eyes), 2.5 mg/0.1 ml (15 eyes) and 5.0 mg/0.2 ml (seven eyes)] of bevacizumab. Best-corrected visual acuity, intraocular pressure and area of corneal neovascularization were measured before injection and at 1 week, 1 month and 3 months after treatment. Results:, At 1 week, the mean neovascularized corneal area decreased significantly to 85.5 ± 18.0% (p = 0.01) in the eyes treated with 2.5 mg bevacizumab and to 73.1 ± 23.4% (p = 0.02) in the eyes treated with 5.0 mg bevacizumab. At 3 months, the mean neovascularized corneal area was 93.6 ± 10.6% (p = 0.10 compared to baseline; p < 0.01 compared to 1 week) in the eyes treated with 2.5 mg bevacizumab and 83.3 ± 25.8% (p = 0.03 compared to baseline; p = 0.02 compared to 1 week) in the eyes treated with 5.0 mg bevacizumab. However, there were no significant changes in the areas of the eyes injected with 1.25 mg bevacizumab. Conclusion:, Subconjunctival injection of bevacizumab can partially reduce corneal neovascularization in the short term, and the efficacy of this treatment correlates with the injection dose. [source] Subconjunctival injection of bevacizumab (Avastin®) for corneal neovascularizationACTA OPHTHALMOLOGICA, Issue 2009MF DE LA PAZ Purpose to study the effects of subconjunctival injection of Bevacizumab on corneal neovascularization. Methods Prospective interventional case series on 7 eyes of 7 patients who underwent subconjunctival injection with Bevacizumab. The following parameters were studied pre-op, at 1 week, 30, 60 and 90 days post-op: UCVA, BCVA, pachymetry with OCT, slit lamp examination and photographic imaging. Conjunctival impression cytology pre-op at 1 week and 9o days was done and complications were also noted. Results Pre-op diagnoses were: herpetic leucoma (4 eyes), chemical burn (2 eyes), neurotrofic keratopathy (1 eye). An informed off-label consent form prior to procedure was signed. 1.25 mg of subconjunctival Bevacizumab was injected nearest the area affected. Mean preoperative UCVA and BCVA were 0.86 and 0.44 LogMar units, improved to 0.61 and 0.26 LogMar units at 90 days post-op, respectively. Central and peripheral pachymetry improved from 532 and 623 microns pre-op, to 529 and 619 microns at 90 days post-op, respectively. All slit lamp findings and photographic imaging showed a clear regression of superficial and deep stromal corneal vascularization, with clearing of lipid deposits around the affected areas. No toxic effects were noted on conjunctival impression cytology. Conclusion Subconjunctival injection of Bevacizumab is a safe and effective procedure for the regression of superficial and deep corneal neovascularization. It may be a good alternative for patients prior to performing an optical keratoplasty or for those who are poor candidates for the same. [source] Intracorneal bevacizumab for treating corneal neovascularization in an experimental rabbit modelACTA OPHTHALMOLOGICA, Issue 2007C PERIS-MARTINEZ Purpose: To evaluate the safety and efficacy of intracorneal and subconjunctival bevacizumab in treating corneal neovascularization in an experimental rabbit model. Methods: Eighteen eyes of 9 animals (New Zealand-female rabbits) participated in this study. For assessment of corneal neovascularization we use an alkali solution (NaOH 1 M). All rabbit eyes developed features of limbal stem cell deficiency like corneal neovascularization, pesistent epithelial defects, etc...The right eye of the animal received 2 injections of bevacizumab (one under conjunctiva and another intracorneal) and left eye will receive two injections of a placebo solution (made of physiological serum) as a control group. Results: One month of follow-up. All control corneas were revascularized to the center. Partial regression of newvessels was observed in 7 out of nine rabbit eyes treated with bevacizumab. Conclusions: On the basis of the results, we suggest that bevacizumab can be effective in reducing corneal neovascularization in this experimental model. [source] Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healingACTA OPHTHALMOLOGICA, Issue 5 2004Lisha Gan Abstract. Purpose:,To study the change in expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the rabbit cornea and limbus following a penetrating, central corneal alkali burn. The influence of different cells on VEGF and VEGFR-2 expression was studied by excluding granulocytes from the wound area. Methods:,Fourteen New Zealand white rabbits were subjected to a penetrating, 5-mm diameter, central corneal alkali burn in one eye under general anaesthesia. Seven of the rabbits were given injections of fucoidin for 36 hours. The rabbits were killed after 36 hours and the corneas were excised with a sclera rim and prepared for immunohistochemistry. Results:,Both VEGF and VEGFR-2 are strongly expressed in the frontline of repopulating epithelial, stromal and endothelial cells during wound healing, irrespective of granulocyte presence. Vascular endothelial cells express VEGF strongly after injury, but only in the presence of granulocytes. Conclusion:,Corneal neovascularization requires the presence of granulocytes to stimulate vascular endothelial cells. During wound healing in this area, VEGF is a factor that stimulates proliferation and migration and that is not influenced by granulocytes. [source] Are we getting closer to prevention and treatment of corneal neovascularization?CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Issue 8 2007Patricia Chévez-Barrios MD No abstract is available for this article. [source] | ||||||||||